Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board & Departure as Chief Scientific Officer
May 13 2019 - 3:00PM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS) (the “Company”), a
late-stage biotechnology company focused on the discovery,
development and commercialization of immunotherapy products, today
announced that Robert Petit, Ph.D. will be leaving his position as
Chief Scientific Officer at the end of the month. Dr. Petit will
assist the Company in transitioning his duties over the next
several weeks, and will continue to support the Company as an
advisor and consultant in his capacity as the new Chair of the
Advaxis Scientific Advisory Board, effective June 3, 2019.
"Advaxis’ clinical and preclinical programs have grown and
matured significantly during Dr. Petit’s time with the Company, and
we are grateful for his guidance and expertise as Chief Scientific
Officer. Over the past several years our business has transitioned
from research and validation to one with a product portfolio
featuring multiple programs in various stages of clinical
development. We appreciate Robert’s work in bringing us to this
point,” said Kenneth A. Berlin, President and Chief Executive
Officer of Advaxis. “On behalf of Advaxis, I would like to thank
Robert for his scientific leadership and extensive contributions to
the Company’s progress. We look forward to his continued support as
Chair of our Scientific Advisory Board."
“Over the past nine years I’ve had the opportunity to guide the
evolution of a technology platform that I continue to believe will
have an important impact on the future of cancer therapies. This
technology has potential to be among the best vectors available for
generating T cell responses against personal and shared neoantigens
and other tumor-specific targets,” said Dr. Petit. “It is with
mixed emotions that I leave my role as the Chief Scientific
Officer, however, I am excited to continue providing scientific
guidance to Advaxis as we progress toward clinical validation of
the platform in furtherance of Advaxis’ mission to improve the
lives of people with cancer.”
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of
proprietary Lm-based antigen delivery products. These
immunotherapies are based on a platform technology that utilizes
live attenuated Listeria monocytogenes (Lm) bioengineered to
secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy and are designed to access and direct antigen
presenting cells to stimulate anti-tumor T cell immunity, activate
the immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable T cells to eliminate tumors. Advaxis has
four programs in various stages of clinical development: ADXS-HPV
for cervical cancer; ADXS-NEO, a personalized neoantigen-directed
therapy for multiple cancers; ADXS-503 for non-small cell lung
cancer, from its ADXS-HOT off-the-shelf neoantigen-directed
program; and ADXS-PSA for prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook and YouTube.
Advaxis Forward-Looking Statement
Some of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. The factors that could
cause our actual results to differ materially include: the success
and timing of our clinical trials, including subject accrual; our
ability to avoid any clinical holds and to resolve FDA’s partial
clinical hold; our ability to obtain and maintain regulatory
approval and/or reimbursement of our product candidates for
marketing; our ability to obtain the appropriate labeling of our
products under any regulatory approval; our plans to develop and
commercialize our products; the successful development and
implementation of our sales and marketing campaigns; the size and
growth of the potential markets for our product candidates and our
ability to serve those markets; our ability to successfully compete
in the potential markets for our product candidates, if
commercialized; regulatory developments in the United States and
other countries; the rate and degree of market acceptance of any of
our product candidates; new products, product candidates or new
uses for existing products or technologies introduced or announced
by our competitors and the timing of these introductions or
announcements; market conditions in the pharmaceutical and
biotechnology sectors; our available cash; the accuracy of our
estimates regarding expenses, future revenues, capital requirements
and needs for additional financing; our ability to obtain
additional funding; our ability to obtain and maintain intellectual
property protection for our product candidates; the success and
timing of our preclinical studies including IND-enabling studies;
the timing of our IND submissions; our ability to get FDA approval
for study amendments; the timing of data read-outs; the ability of
our product candidates to successfully perform in clinical trials;
our ability to initiate, enroll, and execute pilots and clinical
trials; our ability to maintain collaborations; our ability to
manufacture and the performance of third-party manufacturers; the
performance of our clinical research organizations, clinical trial
sponsors and clinical trial investigators; our ability to
successfully implement our strategy; and, other risk factors
identified from time to time in our reports filed with
the SEC. Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We
do not intend to update any of these forward-looking statements to
reflect events or circumstances that occur after the date
hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190513005779/en/
Investors:LHA Investor RelationsYvonne Briggs, (310)
691-7100ybriggs@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024